Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer In Spain- Management in the Later Lines of Therapy
May 1, 2015, 00:00
10.1016/j.jval.2015.03.1175
https://www.valueinhealthjournal.com/article/S1098-3015(15)01232-2/fulltext
Title :
Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer In Spain- Management in the Later Lines of Therapy
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)01232-2&doi=10.1016/j.jval.2015.03.1175
First page :
A203
Section Title :
Cancer
Open access? :
No
Section Order :
641